Richmond Pharmacology are pleased to announce our participation in the American Heart Association’s Hypertension Scientific Sessions 2025, held in Baltimore from 4th –7th September.
Representing Richmond at Hypertension 2025:
Dr Jörg Täubel, Chief Executive Officer
James Rickard, Chief Scientific Officer
Our team will be available to discuss Richmond’s expertise in:
• Early-phase hypertension and cardiovascular research
• First-in-human and dose-response studies
• Ambulatory BP monitoring and novel endpoints
• Regulatory strategy and global trial delivery
• Targeted recruitment and patient-centric design
If you’re attending Hypertension 2025 and seeking a partner in hypertension clinical development, we welcome meeting requests at: info@richmondpharmacology.com
.svg){kind=small}
-min.jpg)
.jpg)
